SecBot SecBot
PRESS-RELEASE ·Filed Mar 9, 2026

KROS

Keros Therapeutics, Inc.
BULLISH
Impact 7/10
Horizonmonths Processed8mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

Traders should monitor upcoming trial initiations and enrollment timelines for the Phase 2 studies in DMD and ALS, as these will be key catalysts. The positive biomarker and safety data reduce near-term clinical risk, potentially supporting valuation upside ahead of clinical milestones.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$11.35
T+0 close · Mar 9, 2026 · via day close
Latest settled
−7.05%
T+60 · $10.55
Vs SPY
−19.04%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 9 $11.35entry
  2. T+1 · 8mo ago +2.03%α +2.21% · $11.58
  3. T+5 · 8mo ago −2.82%α −1.46% · $11.03
  4. T+20 · 7mo ago +7.84%α +10.65% · $12.24
  5. T+60 · 6mo ago −7.05%α −19.04% · $10.55
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Keros Therapeutics presented additional Phase 1 data for rinvatercept (KER-065) at a clinical conference, showing target engagement, favorable changes in muscle and bone mass, and a good safety profile in healthy volunteers. The data support advancing rinvatercept into two Phase 2 trials for Duchenne muscular dystrophy (DMD) and amyotrophic lateral sclerosis (ALS), representing a meaningful step in the clinical development of the drug.

Key Facts

  • Keros presented additional Phase 1 data for rinvatercept in healthy volunteers, confirming target engagement and mechanism of action.
  • Rinvatercept was well-tolerated with no serious adverse events or dose-limiting toxicities.
  • Treatment led to increased muscle mass, decreased fat mass, and improved bone mineral density.
  • Proteomic data showed anti-fibrotic and anti-inflammatory effects, aligning with preclinical findings.
  • Company plans to advance rinvatercept into Phase 2 trials for DMD and ALS.

Financial Impact

No direct financial impact reported; potential long-term value creation if Phase 2 trials succeed.

pipeline valuedevelopment riskinvestor sentiment

Risk Factors

  • Phase 2 trials may not replicate Phase 1 results in patient populations.
  • Clinical development timelines could be delayed due to enrollment, regulatory, or manufacturing challenges.
  • Competition exists in both DMD and ALS spaces with other biotech firms developing novel therapies.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3251751

Track record

27 reports on KROS

Performance horizon

3 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +12.51% at T+60 after the Jul 30, 2026 report. 3 of 3 went positive at some point.

Filters
  1. Nov 16, 2026today Press Release Neutral 2/10 Entry $10.03 Now $10.03 −0.00% settles Dec 16
  2. Nov 12, 20264d ago 144 Neutral 2/10 Entry $10.30 Now $10.03 −2.62% settles Dec 14
  3. Nov 5, 202611d ago 8-K Neutral 3/10 Entry $9.36 Now $10.03 +7.16% settles Dec 7
  4. Nov 5, 202611d ago 8-K Neutral 5/10 Entry $9.36 Now $10.03 +7.16% settles Dec 7
  5. Nov 5, 202611d ago Press Release Neutral 5/10 No price data
  6. Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $11.61 Now $10.03 −13.61% settles Nov 25
  7. Sep 29, 20266w ago 8-K Bullish 6/10 Entry $11.19 to $11.43 Now $10.03 −10.37% ▲ +2.10% +1.39% vs SPY
  8. Sep 28, 20267w ago 8-K Neutral 4/10 Entry $11.28 to $11.33 Now $10.03 −11.08% ▲ +0.44% +0.47% vs SPY
  9. Sep 28, 20267w ago Press Release Neutral 3/10 Entry $11.28 to $11.33 Now $10.03 −11.08% ▲ +0.44% +0.47% vs SPY
  10. Sep 17, 20268w ago EFFECT Neutral 3/10 Entry $11.36 to $11.10 Now $10.03 −11.71% ▼ −2.29% −3.49% vs SPY
Showing 10 of 27

US Market Status

Market Closed · Opens in 6h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 9, 2026